share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/10/29 13:19

Moomoo AI 已提取核心信息

180 Life Sciences has scheduled its 2024 Annual Meeting of Shareholders for December 27, 2024, with October 31, 2024, set as the record date for shareholder voting eligibility. The company reserves the right to modify both the meeting date and record date.Shareholders intending to submit proposals for inclusion in the proxy materials, including director nominations or other business matters, must submit their proposals by November 8, 2024. All submissions must be delivered to the company's principal executive offices in Palo Alto, California. Proposals must comply with SEC rules, Delaware law, and company bylaws to be considered valid.
180 Life Sciences has scheduled its 2024 Annual Meeting of Shareholders for December 27, 2024, with October 31, 2024, set as the record date for shareholder voting eligibility. The company reserves the right to modify both the meeting date and record date.Shareholders intending to submit proposals for inclusion in the proxy materials, including director nominations or other business matters, must submit their proposals by November 8, 2024. All submissions must be delivered to the company's principal executive offices in Palo Alto, California. Proposals must comply with SEC rules, Delaware law, and company bylaws to be considered valid.
180 Life Sciences已定于2024年12月27日召开其2024年年度股东大会,2024年10月31日为股东投票资格的记录日期。公司保留修改会议日期和记录日期的权利。 intending 提交提案以纳入代理材料,包括董事提名或其他业务事项的股东,必须在2024年11月8日之前提交提案。所有提交必须送达公司位于加利福尼亚州帕洛阿尔托的主要执行办公室。提案必须符合SEC规则、特拉华州法律和公司章程才能被视为有效。
180 Life Sciences已定于2024年12月27日召开其2024年年度股东大会,2024年10月31日为股东投票资格的记录日期。公司保留修改会议日期和记录日期的权利。 intending 提交提案以纳入代理材料,包括董事提名或其他业务事项的股东,必须在2024年11月8日之前提交提案。所有提交必须送达公司位于加利福尼亚州帕洛阿尔托的主要执行办公室。提案必须符合SEC规则、特拉华州法律和公司章程才能被视为有效。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息